Background Colorectal cancer (CRC) is common in North America. Metastatic disease is
present at diagnosis in 30% of the patients, and approximately half of early-stage patients …

The treatment of metastatic colorectal cancer (mCRC) has evolved significantly over the past
10 years. For nearly 40 years, the fluoropyrimidine 5-fluorouracil (5-FU) was the only agent …

Abstract Learning Objectives After completing this course, the reader will be able to: Identify
the advantages and disadvantages of the various chemotherapeutic regimens used to treat …

Colorectal carcinoma is one of the most common malignancies in the Western world.
Although fluorouracil (5‐FU) has been used for over 40 years, only in the last decade has its …

During the last decade we have witnessed an unprecedented outburst of new treatment
approaches for the management of metastatic colon cancer. Anti-angiogenic drugs …

The treatment of colorectal cancer has become increasingly complex over recent years. With
the emergence of new chemotherapy drugs and targeted agents, there has been great …

Options for first‐line chemotherapy in patients with metastatic colorectal carcinoma have
broadened considerably with the introduction of irinotecan and oxaliplatin. Furthermore, the …

Opinion statement Despite advances in screening procedures and the use of adjuvant
therapy, approximately 50% of patients with colorectal cancer eventually will develop …

Opinion statement For the past several decades, the therapy for metastatic colorectal cancer
had modest benefits because of the limited therapeutic options. Bolus 5-fluorouracil (5FU) …

Combination chemotherapy regimens including irinotecan and oxaliplatin markedly improve
response rate and prolong median survival over fluorouracil with leucovorin (FU/LV), and …